Cibus Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Cibus Inc reports Q2 loss, eyes commercial transition and growth

Cibus Inc's Q2 2023 performance reflects increased expenses and a net loss, with a focus on commercial transition.
Strengths lie in the efficient Trait Machine process, optimistic market outlook, and strategic collaborations.
Challenges include financial uncertainties, regulatory complexities, and balancing R&D with commercial goals.
Opportunities encompass product expansion, technology extension, M&A potential, and favorable market regulations.

Cibus Inc transitions to commercial focus with promising trait developments

Cibus Inc is transitioning to a commercial focus with promising trait developments in major crops.
Despite a net loss in Q3 2023, the company remains optimistic about future growth opportunities.
Regulatory advancements and strategic realignment position Cibus for potential market expansion.

Cibus Inc excels in gene editing transition, eyes industry growth

Cibus Inc's Q4 performance showcased successful transition, strong market focus, and strategic financial management.
While facing challenges related to merger impacts and spending adjustments, the company remains optimistic about growth opportunities.
With a clear vision for innovation and market leadership, Cibus is poised for continued success in the gene editing agricultural sector.

Cibus Inc (CBUS) reports strong Q1 performance amidst gene editing advancements

Cibus Inc (CBUS) had a strong Q1 2024 performance with revenue exceeding expectations, driven by increased customer demand. The company is navigating challenges in market penetration and increased expenses but sees opportunities in regulatory advances and advancing their gene editing platforms.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded in 2010 and is headquartered in San Diego, CA.

Cibus Applauds the Canadian Food Inspection Agency's (CFIA) New Guidelines for Plants Developed Using Gene Editing Cibus Applauds the Canadian Food Inspection Agency's (CFIA) New Guidelines for Plants Developed Using Gene Editing

Canada Added to a Growing List of Countries Regulating Cibus' Gene Editing Technologies Similar to Conventional Breeding

Cibus, Inc. (NASDAQ:CBUS ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating Officer Conference Call Participants Bobby Burleson - Canaccord Genuity Carol Cheung - Jefferies Steve Byrne - Bank of America Operator Good afternoon, and welcome to the Cibus First Quarter 2024 Results Conference Call. [Operator Instructions] Please also note today's event is being recorded.

Cibus, Inc. (CBUS) Q1 2024 Earnings Call Transcript

Cibus (CBUS) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $5.45 per share a year ago.

Cibus (CBUS) Reports Q1 Loss, Tops Revenue Estimates

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call

Cibus (CBUS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $3 per share a year ago.

Cibus (CBUS) Reports Q4 Loss, Tops Revenue Estimates (Revised)

Cibus (CBUS) Reports Q4 Loss, Tops Revenue Estimates

Cibus, Inc. (CBUS) Q4 2023 Earnings Call Transcript

Completed successful transfers of gene edited elite germplasm back to customers for commercialization for each of its three developed productivity traits: Pod Shatter Reduction (PSR) in Canola and Herbicide Tolerance (HT1 and HT3) in Rice

Cibus Reports Fourth Quarter Financial Results and Provides Business Update

Cibus (CBUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Cibus (CBUS) Moves 6.7% Higher: Will This Strength Last?

SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer will participate in a panel at the 36th Annual Roth Conference taking place March 17-19, 2024.

Cibus to Participate in the 36th Annual Roth Conference

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses Non-GMO plant traits to seed companies, today announced that it has entered into a US Development Agreement with Loveland Products Inc., a subsidiary of Nutrien Ltd. (TSX and NYSE: NTR). Cibus has agreed to collaborate with Loveland Products to provide traits into Loveland's elite rice seed genetics.

Cibus and Loveland Products Collaborate to Develop and Sell Rice Traits in the US

Cibus is a pioneer in the use of gene editing in agriculture, a non-GMO technology that will likely drive the next agricultural revolution. Regulation is a gating market factor for any new crop variety as GMO crops are banned in many markets, and are subject to lengthy regulatory review where permitted. On Feb. 7, the European Parliament approved new regulations that treat gene-edited crops as conventional plant breeding rather than GMO.

EU Greenlights Cibus To Enter Its Massive Market

SAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the Company is moving forward in the next step of commercialization of its developed traits.

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus, a gene editing pioneer in agriculture, has announced collaborations that could significantly increase its revenues. The company has partnered with Interoc to breed rice hybrids with herbicide tolerance for the Latin American market. Further deals in Latin America could double or triple accessible rice acreage. Cibus has also achieved a breakthrough in regenerating wheat plants from single cells, opening up a large addressable market for enhanced forms of wheat.

Cibus: Expanding Opportunities And Growing Accessible Market

SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the Company has successfully regenerated plants from single cells in a wheat cultivar. This is a major breakthrough for Cibus as well as for the industry.

Cibus Announces Major Breakthrough in Wheat Regeneration from Single Cells

Cibus and Interoc announced today they have agreed to a Collaboration Agreement to introduce Cibus' two herbicide tolerance traits for rice growers in Latin America

Cibus Enters into a Latin America Collaboration Agreement with Interoc to deliver rice growers an innovative rice weed control system

SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it has priced an underwritten offering of 2,106,723 shares of its Class A Common Stock and Pre-Funded Warrants to purchase up to 50,000 shares of its Class A Common Stock. The shares of Class A Common Stock are being sold at an offering price of $9.00 per share, before underwriting discounts and commissions, except for shares of Class A Common Stock purchased by an executive officer, which will have an offering price of $10.58 per share, which is the closing bid price for shares of our Class A Common Stock on December 11, 2023. The Pre-Funded Warrants are being sold to one of Cibus' executive officers at an offering price of $10.57, before underwriting discounts and commissions, which is the closing bid price for shares of Class A Common Stock on December 11, 2023, minus $0.01 per share. The Pre-Funded Warrants will have an exercise price of $0.01 per share, will be immediately exercisable and will remain exercisable until exercised in full.

Cibus Announces $20.3 Million Registered Direct Offering

SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, acknowledges the European Union notification to World Trade Organization (WTO) members on the European Commission proposal for regulation of plants obtained from New Genomic Techniques (NGTs) on 31st October. The notification is intended to ensure any potential trade barriers are avoided and invites comments from WTO members by the year end.

European Union Notifies Trading Partners on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that its paper on Industrializing Gene Editing in Brassica napus was published in the International Journal of Plant Biology. (Link Article : https://www.mdpi.com/2037-0164/14/4/77)

Cibus Announces New Publication: Industrial Scale Gene Editing in Brassica napus

Cibus, Inc. (NASDAQ:CBUS ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating Officer Conference Call Participants Bobby Burleson - Canaccord Genuity Kevin Estok - Jefferies Operator Good afternoon, and welcome to the Cibus Third Quarter 2023 Results Conference Call. [Operator Instructions] Please also note, today's event is being recorded.

Cibus, Inc. (CBUS) Q3 2023 Earnings Call Transcript

Gene editing, a non-GMO technology, has the potential to revolutionize agriculture by increasing crop yields, making plants more resilient, and meeting the challenges of climate change. Cibus, a company specializing in gene editing, partners with agricultural giants to develop crops with desirable traits. The company's gene editing technology is protected by roughly 400 issued patents, giving it a significant advantage over competitors.

Cibus: A Pioneer In Gene Editing, The Future Of Agriculture

Cibus (CBUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cibus (CBUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Brandywine Realty

Granite Point Mortgage Trust

Highwoods Properties

Office Properties Income Trust

Vanguard Real Estate ETF

Most REITs have strong balance sheets. But there are exceptions that are heavily overleveraged. I highlight 5 REITs that are risky.

5 REITs That Are Overleveraged

SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ: CBUS), a global leader in Gene Editing in agriculture and the development of Productivity Traits in plants that directly impact farming productivity and profitability announced that its Board of Directors has elected Jim Collins, former CEO of Corteva, to the Board.

Jim Collins to Join Cibus Board of Directors

Cibus, Inc. (NASDAQ:CBUS ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating Officer Conference Call Participants Laurence Alexander - Jefferies Steve Byrne - Bank of America Bobby Burleson - Canaccord Genuity Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Cibus Second Quarter 2023 Financial Results and Corporate Update Conference Call and Webcast.

News for Cibus Inc Stock (CBUS)